Effects of a lipid-based nutrient supplement during pregnancy and lactation on maternal plasma fatty acid status and lipid profile: Results of two randomized controlled trials☆ by Oaks, Brietta M et al.
Contents lists available at ScienceDirect
Prostaglandins, Leukotrienes and Essential Fatty Acids
journal homepage: www.elsevier.com/locate/plefa
Eﬀects of a lipid-based nutrient supplement during pregnancy and lactation
on maternal plasma fatty acid status and lipid proﬁle: Results of two
randomized controlled trials☆
Brietta M. Oaksa,⁎, Rebecca R. Younga, Seth Adu-Afarwuahb, Ulla Ashornc, Kristina H. Jacksond,
Anna Larteyb, Kenneth Maletae, Harriet Okronipaa, John Sadalakie, Lacey M. Baldiviezf,
Setti Shahab-Ferdowsf, Per Ashornc,g, Kathryn G. Deweya
a Program in International and Community Nutrition, Department of Nutrition, University of California, 3135 Meyer Hall, One Shields Avenue, Davis, CA
95616, USA
b Department of Nutrition and Food Science, University of Ghana, Legon, Ghana
c Center for Child Health Research, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland
d OmegaQuant Analytics, LLC, Sioux Falls, SD, USA
e University of Malawi College of Medicine, Department of Community Health, Blantyre, Malawi
f USDA, ARS Western Human Nutrition Research Center, Davis, CA, USA
g Department of Paediatrics, Tampere University Hospital, Tampere, Finland








A B S T R A C T
It is unknown whether a novel small-quantity lipid-based nutrient supplement (SQ-LNS) containing alpha-
linolenic (ALA) and linoleic acids impacts maternal plasma lipids and fatty acid status. We measured plasma
fatty acids (wt%) and lipid concentrations at 36 wk gestation and breast milk fatty acids (wt%) at 6 months
postpartum in a subsample of women enrolled in a randomized controlled trial studying the eﬀects of SQ-LNS
on birth outcomes and child growth. Women≤20 wk gestation in Ghana (n=1,320) and Malawi (n=1,391) were
assigned to receive daily either: 1) iron-folic acid (pregnancy); 2) multiple micronutrients (pregnancy and
lactation); or 3) SQ-LNS (pregnancy and lactation). At 36 wk, plasma ALA levels were higher in those receiving
SQ-LNS. SQ-LNS increased breast milk ALA in Ghana but not Malawi. There was no eﬀect on plasma lipids or
other selected fatty acids. SQ-LNS may impact plasma and breast milk ALA levels depending on the population.
1. Introduction
Adequate amounts of the essential polyunsaturated fatty acids
(PUFAs) alpha-linolenic acid (ALA, omega-3) and linoleic acid (LA,
omega-6) are required during pregnancy and lactation for optimal fetal
and infant growth [1]. Fatty acids are transferred to the fetus during
pregnancy through the placenta and continue to be provided during
infancy through the mother's milk. Thus, fatty acid consumption and
body stores of the mother have a direct eﬀect on fetal and infant fatty
acid status [1]. Fatty acid supplementation trials in pregnant popula-
tions have primarily focused on the long-chain fatty acid derivatives of
ALA – docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
[2] – due to the accumulation of DHA in the brain and retina and the
low conversion rate of ALA to DHA (approximately 9% of ALA converts
to DHA in women) [3]. However, several studies in non-pregnant
populations suggest that biomarkers of ALA status are associated with
health beneﬁts independent of DHA [4,5].
Only one trial to date, conducted in the Netherlands, has examined
the eﬀect of maternal ALA supplementation on fatty acid status during
pregnancy [6]. ALA supplementation led to higher concentrations of
ALA, eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA)
(wt%) in maternal plasma at delivery but had no eﬀect on DHA or AA.
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A summary of ALA supplementation studies (all non-pregnant parti-
cipants, although some studies included breastfeeding women) also
indicated that ALA supplementation generally resulted in increases in
plasma and breast milk ALA but had little eﬀect on DHA [7]. However,
the majority of these studies have been conducted in Europe and North
America, and it is possible that populations with poorer nutritional
status might respond diﬀerently to ALA supplementation, as various
factors can aﬀect the conversion of ALA to DHA (e.g., diets in Europe
and North America are high in LA, which inhibits conversion of ALA to
DHA) [8]. In many populations, total energy intake among pregnant
and lactating women may be adequate, but the ALA and AA content of
the usual diet may be low [9]. While estimates speciﬁc to ALA and AA
are not available, it is estimated that the availability of omega-3 fatty
acids in the food supply of Ghana ( < 0.4% of energy supply) and
Malawi ( < 0.3% of energy supply) is below the minimum recom-
mended level (0.5% of energy supply) to meet the needs of pregnant
and lactating women in the populations [9].
Additionally, low maternal plasma cholesterol during pregnancy
has been associated with adverse birth outcomes, such as preterm birth
[10,11]. Cholesterol is required for the structural integrity of cell
membranes and as a precursor to steroid hormones [12,13], and is
therefore essential during pregnancy for fetal cell formation and
placental steroid hormone production [14]. At the same time, high
cholesterol and triglycerides are also associated with adverse birth
outcomes [15,16]. In Ghana, both low and high cholesterol may be a
concern. A trial conducted in Ghana in non-pregnant healthy adults
showed that peanut consumption over the course of 30 wk reduced
total plasma cholesterol and triglyceride concentrations [17].
Small-quantity lipid-based nutrient supplements (SQ-LNS) are a
novel form of nutritional supplementation that deliver micronutrients
in a food-base along with protein, fat, and essential fatty acids (EFA).
SQ-LNS are currently being studied as a home fortiﬁcant in lower- and
middle-income countries to prevent malnutrition, particularly in
women and children. We reported previously that compared with
iron-folic acid (IFA) and multiple micronutrient (MMN) capsules,
providing a peanut-based SQ-LNS to pregnant and lactating women
in Ghana promoted fetal growth in vulnerable women, such as
primiparas, and had a positive eﬀect on child growth [18,19], but
had no signiﬁcant eﬀect on newborn birth size or child growth in
Malawi [20,21]. While several other studies have also examined the
impact of SQ-LNS on birth size or child growth [22–24], no study has
yet examined whether SQ-LNS have an eﬀect on biomarkers of
maternal fatty acid status, even though a key aspect that distinguishes
SQ-LNS from other nutritional supplements proposed for lower- and
middle-income countries is that it contains EFA.
The objective of the present study was to determine the eﬀects of
SQ-LNS provided to women during pregnancy and lactation on
maternal plasma fatty acids and lipids and breast milk fatty acids. To
address this objective, we compared plasma fatty acids and lipid
concentrations at 36 wk gestation and breast milk fatty acids at 6 mo
postpartum of women receiving SQ-LNS during pregnancy and lacta-
tion with those of women receiving either IFA (during pregnancy only)
or MMN (during pregnancy and lactation). Our primary hypotheses
were that compared to women who received IFA or MMN, women who
received SQ-LNS during pregnancy and lactation would have: 1) lower
mean plasma total cholesterol and triglyceride concentrations and a
lower prevalence of low total cholesterol ( < 10th percentile of IFA
group) at 36 wk gestation; and 2) higher levels of ALA and LA in
plasma at 36 wk gestation and in breast milk at 6 mo postpartum.
2. Participants and methods
2.1. Participants and study design
This was a sub-study of participants from two randomized con-
trolled trials conducted in Malawi and Ghana as part of the
International Lipid-Based Nutrient Supplements (iLiNS) Project
(www.ilins.org). The primary objective of these trials was to
determine the eﬀect of SQ-LNS, provided during pregnancy,
lactation, and early childhood, on child growth at 18 months of age,
as compared with IFA provided during pregnancy or MMN provided to
the mother during pregnancy and the ﬁrst six months postpartum.
Details of the study methods have been reported elsewhere [18,20,21].
Brieﬂy, the study teams in Ghana and Malawi recruited women
attending prenatal care visits at four health facilities in semi-urban
areas of the Yilo Krobo and Lower Manya Krobo districts about 70 km
north of Accra, Ghana between December 2009 and December 2011,
and four health facilities in the rural Mangochi district in southern
Malawi between February 2011 and August 2012. While the trials were
similar in design, each trial operated independently and there were
some diﬀerences in inclusion/exclusion criteria. In Ghana, women
were eligible if they were: ≤20 wk gestation (conﬁrmed by ultrasound),
≥18 y of age, had a completed antenatal health card, and signed or
thumb-printed informed consent. We excluded women if they were:
HIV positive, had asthma, epilepsy, tuberculosis, a chronic disease that
required medical attention, did not reside in the deﬁned catchment
area, had a milk or peanut allergy, or were participating in another
clinical trial. The Malawi trial had similar exclusion and inclusion
criteria, however women in Malawi were eligible if they were ≥15 y of
age and were not excluded if they were HIV positive. A daily iron and
folic acid capsule is the standard of care during pregnancy in both
countries. In Malawi, nutritional supplementation before or after
pregnancy is not common. In Ghana, women continue to receive the
iron and folic acid capsule 6 wk after delivery and receive high dose
vitamin A within 8 wk after delivery, and the use of dietary and herbal
supplements in the study setting is common. Women were enrolled in
the trials at a mean of 16–17 wk gestation and received
supplementation through pregnancy and until 6 months postpartum,
which represents an average of 56 wk of supplementation.
In both trials, pregnant women were randomized to receive one of
the following three daily treatments: 1) iron and folic acid (IFA, a
capsule consisting of 60 mg iron and 400 µg folic acid, received during
pregnancy only); 2) multiple micronutrients (MMN, a capsule consist-
ing of 18 vitamins and minerals [including 20 mg iron], received
during pregnancy and the ﬁrst 6 months postpartum); or 3) SQ-LNS
(a 20 g sachet which included the same 18 micronutrients as the MMN
capsule plus four additional minerals: calcium, phosphorus, potassium,
magnesium) (see Table 1 for nutrient content of each supplement).
Both the IFA and MMN groups were considered control groups. Group
allocations were determined by a statistician who used a computer-
generated randomization scheme in blocks of 9 (3 codes for each of the
3 interventions) and codes were placed in sealed opaque envelopes. A
woman chose an envelope from a stack of envelopes (6 and 9 envelopes
per stack in Malawi and Ghana, respectively) to determine her group
allocation and received her ﬁrst 2-wk supplement ration at this time.
Field workers made home visits biweekly, during which they delivered
the supplements and collected information on the participant's ad-
herence to the study intervention. Adherence was assessed by maternal
report as well as by counting the numbers of unconsumed capsules or
sachets. This was a partially-blinded trial, as it was not possible to blind
the ﬁeldworkers and study participants to those consuming capsules vs.
SQ-LNS (because of the starkly diﬀerent characteristics).
In Ghana, from the 1,320 women enrolled in the trial, 510 were
excluded from the present analysis due to an error in the labeling of the
IFA and MMN supplements, resulting in mixed exposure [18]. From
the remaining 810 women, enrolled from October 2010 to December
2011, 369 women were randomly selected for analysis of blood lipids
and fatty acids (Supplementary Fig. 1). In Malawi, from the 1,391
women enrolled in the trial, 315 women were randomly selected for
analysis of fatty acids and all 1,391 for blood lipids (Supplementary
Fig. 2).
The institutional review boards at the College of Medicine Research,
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University of Malawi and the Ethics Committee of Pirkanmaa Hospital
District, Finland approved the study protocol for the trial in Malawi.
The institutional review boards at the University of California, Davis;
the Noguchi Memorial Institute for Medical Research, University of
Ghana; and the Ghana Health Service approved the study protocol for
the trial in Ghana. Both trials were registered at www.clinicaltrials.gov
(IDs: NCT01239693, NCT00970866).
2.2. Breast milk and blood sample collection
At both sites, study nurses collected venous blood samples from
women at enrollment and 36 wk gestation into a heparin-treated, trace
element-free, Sarstedt Monovette tube. Because of the diﬃculty of
obtaining fasting blood samples from pregnant women, non-fasting
blood samples were collected. However, we collected information
regarding time between last meal and sample collection. Lab techni-
cians centrifuged the blood samples at 4000 rpm for 15 min to obtain
plasma. Breast milk was collected at 6 months postpartum. In Ghana,
study nurses assisted women in collecting a 10–20 mL mid-stream
breast milk sample during a follow-up clinic visit. In Malawi, women
expressed a full milk sample from a single breast during a home visit. A
trained ﬁeld worker then mixed the breast milk and collected a 10 mL
sample, with the remaining milk provided to the infant by spoon. All
samples were stored at −20 °C within 24 h of collection and moved to
−80 °C for longer term storage.
2.3. Cholesterol and triglyceride analysis
Plasma samples from the Ghana trial were analyzed in Accra,
Ghana for total cholesterol, HDL-C, and triglyceride concentrations
using a Flexor Junior Chemistry Analyzer (Vital Scientiﬁc, Dieren,
Netherlands). LDL-C was calculated using the Friedewald equation:
LDL-C=total cholesterol–(HDL-C)–(triglycerides/5), mg/dL [25]. This
is accepted as an accurate method of determining LDL-C concentra-
tion, as long as triglyceride concentration is not ≥400 mg/dL [25,26];
all of our samples were below this level. Plasma samples from the
Malawi trial were shipped on dry ice to Davis, CA, where lab
technicians quantiﬁed total cholesterol and triglyceride concentrations
by enzymatic colorimetric assay using a Cobas Integra 400 plus
automatic analyzer (Roche Diagnostic Corp., Indianapolis, IN). All
lab technicians were blinded to the intervention groups.
2.4. Fatty acids analysis
Plasma and breast milk samples from both trials were shipped to
OmegaQuant Analytics (Sioux Falls, SD) for analysis of fatty acids.
Fatty acid composition was analyzed by gas chromatography with ﬂame
ionization detection. Plasma or breast milk was added to a mixture of
solvents (methanol containing 14% boron triﬂuoride: toluene: metha-
nol; 35:30:35 v/v/v, all from Sigma-Aldrich, St. Louis, MO). The tube
was vortexed and heated in a hot bath at 100 °C for 45 min. After
cooling, hexane (EMD Chemicals, USA) and distilled water were added.
The sample was vortexed and centrifuged, and then an aliquot of the
hexane phase was analyzed by gas chromatography using a GC-2010
(Shimadzu Corporation, Columbia, MD) equipped with a SP-2560,
100-m fused silica capillary column (0.25 mm internal diameter,
0.2 µm ﬁlm thickness; Supelco, Bellefonte, PA). Fatty acid composition
was expressed as a percent by weight (wt%) of total identiﬁed fatty
acids. All lab technicians were blinded to the intervention groups.
2.5. Maternal characteristics
At enrollment, anthropometrists measured weight and height using
high-quality scales and stadiometers. We calculated body mass index
(BMI = kg/m2). Lab technicians assessed malaria and HIV infection
status with rapid tests. Concentrations of inﬂammatory biomarkers C-
reactive protein (CRP, mg/L) and alpha-1 glycoprotein (AGP, g/L)
were measured in plasma by immunoturbidimetric assay using the
autoanalyzers speciﬁed earlier. Trained interviewers collected socio-
economic and demographic information at a follow-up home visit.
2.6. Sample size and statistical analysis
For analysis of fatty acids and lipid concentrations, we used a
minimum eﬀect size (Cohen's d) of 0.5 to calculate sample size,
assuming a two-sided α=0.05% and 80% power, requiring a subsample
of 79 per group (total n=237). Allowing for attrition and women
missing a sample at either baseline or 36 wk gestation, 369 women
were randomly selected from the 810 women in Ghana enrolled after
October 1, 2010. In Malawi, 315 women were randomly selected from
women with blood samples at both baseline and 36 wk gestation and a
breast milk sample at 6 months postpartum. The eﬀect of the
intervention on cholesterol and triglyceride concentrations was exam-
ined in the full sample in Malawi and in the subsample in Ghana.
Statistical analysis was performed according to intention-to-treat
and focused on examining diﬀerences between the three intervention
groups in plasma fatty acid levels and lipid concentrations at 36 wk
gestation and breast milk fatty acid levels at 6 months postpartum. The
primary fatty acids of interest were ALA and LA. Secondarily, to
determine if there was any impact on LCPUFAs, we also examined the
eﬀect of supplementation on DHA, EPA, AA, the sum of DHA and EPA,
the sum of all long chain omega-3 fatty acids (DHA, EPA, and DPA),
and the following ratios: LA:AA, ALA:DHA, AA:EPA, and omega-6 fatty
acids:omega-3 fatty acids. We limited our analyses to these fatty acids
and ratios as indicators of LCPUFA metabolism and due to their
potential eﬀects on infant growth and neurodevelopment [1,3].
Cholesterol and triglycerides were analyzed as concentrations, and
fatty acids were analyzed as percentage of total fatty acids (by weight).
Logarithmic transformation of all fatty acid variables and triglyceride
concentration was applied to approximate a normal distribution of the
data which was evaluated using the Shapiro-Wilk test. Fatty acids were
Table 1
Nutrient composition of supplements used in the study: iron and folic acid (IFA) capsule,
multiple micronutrient (MMN) capsule, and small-quantity lipid-based nutrient
supplement (SQ-LNS).
Nutrient IFA MMN SQ-LNS (20 g)
Energy (kcal) 0 0 118
Protein (g) 0 0 2.6
Fat (g) 0 0 10
Linoleic acid (g) 0 0 4.59
α-linolenic acid (g) 0 0 0.59
Iron (mg, ferrous sulphate) 60 20 20
Folic acid (µg, pteroyl monoglutamic acid) 400 400 400
Vitamin A (µg RE, retinyl acetate) 0 800 800
Vitamin B12 (µg, cyanocobalamin 0.1%) 0 5.2 5.2
Vitamin B6 (mg, pyridoxine hydrochloride) 0 3.8 3.8
Vitamin C (mg, L-ascorbic acid) 0 100 100
Vitamin D (IU, cholecalciferol [D3]) 0 400 400
Zinc (mg, zinc sulphate) 0 30 30
Thiamin (mg, thiamin hydrochloride) 0 2.8 2.8
Riboﬂavin (mg, riboﬂavin) 0 2.8 2.8
Niacin (mg, niacinamide) 0 36 36
Vitamin E (mg, DL-α-tocopherol acetate) 0 20 20
Vitamin K (µg, phylloquinone 5%) 0 45 45
Pantothenic acid (mg, calcium pantothenate) 0 7 7
Copper (mg, encapsulated copper sulphate) 0 4 4
Iodine (µg, potassium iodate) 0 250 250
Manganese (mg, manganese sulphate) 0 2.6 2.6
Selenium (µg, sodium selenite 1.5%) 0 130 130
Calcium (mg, tricalcium phosphate) 0 0 280
Phosphorus (mg, tricalcium phosphate) 0 0 190
Potassium (mg, potassium chloride) 0 0 200
Magnesium (mg, magnesium citrate) 0 0 65
Phytate (mg) 0 0 24.7
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dichotomized into high or low values using a median cut-point and low
cholesterol was deﬁned as < 10th percentile of the IFA group at 36 wk
gestation. We also used the following clinical deﬁnitions: high total
cholesterol (≥240 mg/dL), high LDL-C (≥160 mg/dL), and low HDL-C
( < 50 mg/dL) [27,28].
We used the Household Food Insecurity Access Scale [29] to
estimate food insecurity and created scores using standard criteria
adjusted for the month of collection. An asset index was created using
principal components analysis [30] based on household ownership of a
set of assets (radio, television, cell phone, bed, mattress, bed net, and
bicycle), lighting source, drinking water supply, sanitation facilities,
and ﬂooring materials.
We evaluated the eﬀect of the nutritional intervention on lipids and
fatty acids in plasma using ANCOVA (continuous outcomes) and
logistic regression (binary outcomes) models, using the Tukey-
Kramer adjustment for multiple comparisons and p < 0.05 indicating
statistical signiﬁcance. We performed analyses both with and without
covariates, as guidelines for best statistical practices support the use of
covariates in analyses of randomized controlled trials [31]. All models
included the baseline value for the outcome variable. This is mathe-
matically the same as testing for a diﬀerence in the change in the
outcome (between baseline and 36 wk) between the three groups. We
used similar statistical analyses for fatty acids in breast milk, although
those models could not include a baseline value, and we only had one
time point for breast milk sample collection. Pooled analyses included
trial site in all models. We considered covariates for inclusion in the
model if they were associated with the outcome variable at p < 0.1.
Potential covariates were selected from previous literature and stated
in a predeﬁned analysis plan; they included baseline measurement of
the outcome variable, gestational age, maternal age, education level,
BMI and height, season of enrollment, malaria infection, HIV status
(Malawi only), inﬂammatory markers, household food insecurity, asset
index, parity, site of enrollment, and time since last meal.
To determine whether a pooled data analysis could be conducted,
we tested for interaction between study site and intervention group. We
also tested for interaction between the intervention group and maternal
age, parity, and baseline BMI. All interactions were evaluated in linear
regression models and interaction term p-values < 0.1 were considered
to be statistically signiﬁcant. We compared baseline characteristics
between women in each of the three intervention groups, as well as
between those with complete data and those with missing data at 36 wk
gestation, as this time point has the largest proportion of missing data.
In sensitivity analyses, we performed unadjusted analyses using the
same sample that was used in adjusted analyses, and considered a >
10% change in results to be indicative of bias. We also performed
another sensitivity analysis to compare those receiving LNS with those
not receiving LNS (IFA group and MMN group combined) for all
outcomes. Model assumptions were checked using standard regression
diagnostics for linearity, normality, leverage, and inﬂuence. All ana-
lyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
3. Results
At enrollment, plasma fatty acid data were available for 628 women
(313 in Ghana, 315 in Malawi) and plasma lipid data for 1,718 women
(347 in Ghana, 1,371 in Malawi). At 36 wk gestation, plasma fatty acid
and lipid data from follow-up visits were available for 536 (221 in
Ghana, 315 in Malawi) and 1,365 (298 in Ghana, 1,067 in Malawi)
women, respectively. At 6 months postpartum, breast milk fatty acid
data were available for 618 women (303 in Ghana, 315 in Malawi).
Loss-to-follow-up did not diﬀer by intervention group in either trial.
We compared women with missing data at 36 wk gestation with those
who had complete data (Supplementary Table 1). Women with
complete blood lipid data in Malawi diﬀered in some baseline
characteristics and had lower mean baseline cholesterol (121 vs.
125 mg/dL, p=0.04) and triglyceride (95 vs. 101 mg/dL, p=0.02)
concentrations than those with complete data. Women in Ghana with
complete plasma fatty acid data had higher mean concentration of
DHA at baseline (5.1 vs. 4.9%, p=0.04), but were otherwise similar.
Baseline maternal characteristics did not diﬀer by intervention
group in either site (Table 2). Baseline values for blood lipids and fatty
acids were generally similar among intervention groups within each
trial, although AA and triglyceride levels were higher in the IFA group
in Malawi (Table 3). There was no signiﬁcant interaction between study
site and intervention group, which allowed for pooled analyses.
However, given the diﬀerences in baseline fatty acid and blood lipid
levels between the two trials, analyses were also conducted for each
trial separately. A comparison of the fatty acid proﬁles of women in the
two countries is presented in Fig. 1 and Fig. 2.
At 36 wk gestation in the Malawi trial, a group diﬀerence in mean
plasma ALA was evident in the adjusted model (p=0.04), with women
receiving SQ-LNS demonstrating higher values compared with women
receiving MMN (SQ-LNS: 0.49, MMN: 0.44 wt%, Tukey-adjusted
p=0.04). In the Ghana trial, a signiﬁcant group diﬀerence was seen
in the ALA:DHA ratio in plasma at 36 wk gestation (p=0.03) and breast
milk at 6 months postpartum (p=0.03) (fatty acid ratio results in
Supplementary Table 2), with signiﬁcant diﬀerences of the ALA:DHA
ratio between SQ-LNS and IFA in plasma (ratio: 0.07 vs. 0.06, p=0.03)
and between SQ-LNS and MMN in breast milk (ratio: 0.48 vs. 0.39,
p=0.02). There was a signiﬁcant diﬀerence in mean plasma ALA in
pooled analyses (p=0.04) (Table 3), which remained signiﬁcant in
analyses adjusted for selected covariates (p=0.02). The SQ-LNS group
had higher ALA levels compared with either the group receiving MMN
(SQ-LNS: 0.38, MMN: 0.35% wt, Tukey-adjusted p=0.06) or IFA (SQ-
Table 2
Baseline characteristics of the participating women at enrollment by study group.a
Ghana Malawi
Characteristic IFA (n=124) MMN (n=121) SQ-LNS (n=124) Pc IFA (n=457) MMN (n=463) SQ-LNS (n=453) Pc
Maternal age, years 26.3 (5.0) 26.3 (5.5) 27.0 (5.4) 0.53 25.0 (6.1) 24.8 (6.1) 25.1 (6.2) 0.79
Education, completed years 7.4 (3.3) 7.2 (3.3) 7.9 (3.7) 0.19 3.9 (3.4) 4.1 (3.4) 4.1 (3.6) 0.57
Primiparous women 38.9% 34.9% 31.6% 0.46 20.4% 23.2% 22.4% 0.58
Gestational age at enrollment, weeks 16.3 (3.3) 16.2 (3.0) 16.2 (3.1) 0.97 16.8 (2.1) 16.8 (2.1) 16.9 (2.2) 0.91
Body mass index (BMI), kg/m2 24.7 (4.2) 24.7 (4.1) 24.8 (3.8) 0.98 22.1 (2.6) 22.2 (2.9) 22.2 (3.0) 0.58
Women with anemia (Hb < 100 g/l) 11.5% 16.7% 13.5% 0.47 21.2% 20.0% 21.4% 0.84
Women overweight or obese BMI (≥25 kg/m2) 42.3% 40.3% 39.2% 0.88 13.2% 12.4% 13.3% 0.91
Women with a low BMI ( < 18.5 kg/m2) 2.9% 1.6% 0.8% 0.46 6.0% 4.6% 5.8% 0.60
Women with a positive HIV testb – – – – 15.5% 11.2% 14.2% 0.15
Women with a positive malaria test (RDT) 6.5% 4.8% 9.0% 0.42 22.3% 24.2% 23.3% 0.79
a Mean (SD) except where noted.
b HIV positive women were excluded from the trial in Ghana.
c p-value obtained from ANOVA (comparison of means) or Fisher's exact test (comparison of proportions).
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Table 3
Median plasma ALA, LA, DHA, AA, and n6:n3 ratio and mean maternal plasma lipids by intervention group.
Ghana Malawi Pooled
IFA MMN SQ-LNS pg IFA MMN SQ-LNS pg pg
Fatty Acids (n=110)c (n=98)c (n=105)c (n=103) (n=106) (n=106)
ALA, wt%
Enrollment 0.28 0.26 0.25 0.07 0.46 0.50 0.42 0.22 0.21
(0.23, 0.34)d (0.23, 0.31) (0.22, 0.32) (0.35, 0.61) (0.38, 0.64) (0.37, 0.54)
36 wka 0.26 0.26 0.27 0.10 0.47 0.45 0.48 0.18 0.04h
(0.22, 0.30) (0.21, 0.32) (0.23, 0.32) (0.35, 0.59) (0.35, 0.55) (0.37, 0.59)
LA, wt%
Enrollment 23.9 23.5 23.1 0.27 25.4 25.6 25.6 0.42 0.18
(21.6, 25.0) (21.6, 25.0) (21.3, 24.6) (22.9, 27.1) (23.3, 28.1) (22.6, 27.7)
36 wka 22.0 22.1 22.6 0.13 25.2 25.8 25.6 0.28 0.14
(20.1, 23.7) (20.2, 24.1) (20.5, 24.6) (23.3, 27.5) (23.7, 28.5) (23.1, 28.5)
DHA, wt%
Enrollment 5.08 4.99 5.06 0.29 4.62 4.28 4.38 0.62 0.34
(4.39, 5.65) (4.41, 5.63) (4.61, 5.81) (3.65, 5.17) (3.53, 5.01) (3.75, 5.00)
36 wka 4.01 3.72 3.87 0.56 3.59 3.61 3.57 0.95 0.80
(3.33, 4.64) (3.27, 4.39) (3.41, 4.54) (3.01, 4.13) (2.89, 4.24) (3.07, 4.14)
AA, wt%
Enrollment 6.09 6.24 5.90 0.24 8.30 7.74 7.89 0.04 0.52
(5.38, 6.87) (5.69, 7.23) (5.34, 6.60) (7.17, 9.36) (7.03, 8.53) (7.11, 8.88)
36 wka 4.94 5.09 5.12 0.37 6.68 6.60 6.41 0.12 0.68
(4.45, 5.48) (4.29, 5.69) (4.51, 5.56) (5.91, 7.54) (5.87, 7.21) (5.66, 7.04)
n6:n3
Enrollment 4.5 4.5 4.3 0.19 5.9 6.3 6.2 0.56 0.20
(3.9, 5.3) (3.8, 5.4) (3.8, 4.9) (5.0, 7.5) (5.0, 7.5) (5.1, 7.2)
36 wka 5.4 5.6 5.5 0.35 7.3 7.2 7.3 0.79 0.59
(4.4, 6.4) (4.7, 7.2) (4.6, 6.5) (6.1, 8.8) (6.0, 9.1) (6.0, 8.6)
Plasma Lipids (n=115)e (n=117)e (n=115)e (n=457)e (n=463)e (n=453)e
Cholesterol, mg/dL
Enrollment 144.0 ± 33.3f 142.6 ± 32.2 145.2 ± 37.7 0.85 122.1 ± 32.4 121.3 ± 30.3 120.9 ± 30.7 0.84 0.89
36 wk 165.5 ± 41.0 163.5 ± 40.2 166.6 ± 43.5 0.86 149.6 ± 36.1 151.0 ± 39.0 150.9 ± 37.2 0.86 0.87
HDL-C, mg/dLb
Enrollment 56.3 ± 21.5 54.5 ± 21.3 59.0 ± 24.2 0.31 – – – – –
36 wk 66.6 ± 29.7 66.0 ± 29.3 67.7 ± 31.6 0.92 – – – – –
LDL-C, mg/dLb
Enrollment 63.5 ± 28.7 64.3 ± 25.5 63.7 ± 29.0 0.98 – – – – –
36 wk 68.8 ± 32.9 68.8 ± 31.8 68.8 ± 34.9 1.00 – – – – –
Triglycerides, mg/dL
Enrollment 125.9 ± 57.3 114.2 ± 55.7 115.4 ± 59.1 0.23 99.8 ± 43.1 94.1 ± 34.6 94.5 ± 35.8 0.04 0.01
36 wk 146.8 ± 76.1 144.2 ± 70.4 149.9 ± 74.9 0.86 150.8 ± 62.6 147.4 ± 61.4 150.0 ± 63.6 0.75 0.68
a Model includes baseline value of outcome variable for reported p-value.
b HDL-C and LDL-C were not measured in Malawi.
c For plasma fatty acids at 36 wk gestation in Ghana, IFA: n=69, MMN: n=77, SQ-LNS: n=75
d Median (25th percentile, 75th percentile), all such values.
e For plasma lipids at 36 wk gestation in Ghana, IFA: n=95, MMN: n=104, SQ-LNS: n=99, and in Malawi, IFA: n=352, MMN: n=362, SQ-LNS: n=352.
f Mean ± SD, all such values.
g P-values obtained by ANOVA (baseline analyses) and ANCOVA (36 wk gestation analyses).
h Two pairwise comparisons had a p-value < 0.10: 1) SQ-LNS vs. MMN, Tukey-adjusted p=0.06; and 2) SQ-LNS vs. IFA, Tukey-adjusted p=0.08.
Fig. 1. Fatty acid proﬁle of maternal plasma at enrollment and 36 wk gestation and breast milk at 6 mo postpartum.
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LNS: 0.38, IFA: 0.36% wt, Tukey-adjusted p=0.08). No other diﬀer-
ences in fatty acid levels or ratios or blood lipid concentrations between
groups were signiﬁcant. There was no diﬀerence in the proportion of
women with low plasma cholesterol ( < 10th percentile of IFA group)
across the intervention groups in either unadjusted or adjusted
analyses.
At 6 months postpartum, women receiving SQ-LNS in the Ghana
trial had higher ALA levels in breast milk (p=0.02) and a higher ratio of
ALA:AA (SQ-LNS: 1.07, MMN: 0.95: Tukey-adjusted p=0.02) in breast
milk compared with women receiving MMN. See Table 4 for selected
results. These diﬀerences became non-signiﬁcant in adjusted analyses
(data not shown). In the Malawi trial and pooled analyses, breast milk
fatty acid levels and fatty acid ratios were not signiﬁcantly diﬀerent
across intervention groups in either unadjusted or adjusted analyses.
4. Discussion and conclusion
4.1. Discussion
As SQ-LNS are novel nutritional supplements, this research aimed
to determine the eﬀect of SQ-LNS during pregnancy and lactation on
maternal plasma fatty acid status and lipid concentrations. We found
no signiﬁcant diﬀerence in plasma fatty acid levels or lipid concentra-
tions in Ghana or Malawi at 36 wk gestation, although pooled results
suggest that SQ-LNS supplementation increases mean maternal plas-
ma ALA levels during pregnancy. SQ-LNS increased ALA levels in
breast milk in Ghana but did not impact breast milk fatty acid levels in
Malawi.
In terms of DHA, our results are consistent with previous ALA
supplementation trials. A review by Brenna et al. reported that out of
21 such trials, only 7 trials reported an eﬀect on DHA [7], although
other omega-3 LCPUFAs (EPA, DPA) were typically higher in plasma
from participants receiving ALA. It is possible that the lack of an eﬀect
on LCPUFAs is due to the amount of ALA (0.59 g) in SQ-LNS, as all of
the trials in the review used higher ALA doses (range: 1.5–40 g). It is
also possible that SQ-LNS had a limited impact on plasma and breast
milk fatty acids because it also included 4.59 g LA. A recent review of
the eﬀect of dietary modiﬁcation of ALA and LA showed that reducing
LA intake was a key factor for increasing omega-3 LCPUFA levels [32].
It is likely that women in the study area in Malawi regularly
consume ﬁsh high in DHA and AA and plant oils that are high in LA
and low in ALA [33]. Food and Agriculture Organization (FAO) balance
sheets also support the possibility of high ﬁsh consumption in Ghana
and use of high LA/low ALA oils [9]. Breast milk DHA levels were 2
and 3 times higher in Malawi and Ghana, respectively, than the
worldwide average (0.32 ± 0.22% [full range: 0.06–1.40%]) established
by Brenna et al. [34] As a point of reference, Ghanaian milk DHA levels
were comparable to Japanese levels, where ﬁsh intake is very high.
Both African cohorts had substantially higher milk DHA levels than in
the US (~0.2% [35]) and other industrialized countries. The milk AA
values were within the normal range described by Brenna et al. [34]
(0.47 ± 0.13% [full range: 0.24–1.0%]), with the Malawi values on the
Fig. 2. ‘Other’ fatty acids category from Fig. 1 expanded.
Table 4
Median breast milk ALA, LA, DHA, AA, and n6:n3 ratio by intervention group at 6 months postpartum.
Ghana Malawi Pooled
IFA (n=102) MMN (n=100) SQ-LNS (n=101) pa IFA (n=103) MMN (n=106) SQ-LNS (n=106) pa pa
ALA, wt% 0.41b 0.38 0.44 0.02 0.59 0.63 0.64 0.33 0.11
(0.39, 0.44) (0.36, 0.40) (0.40, 0.47) (0.54, 0.63) (0.57, 0.68) (0.59, 0.69)
LA, wt% 10.4 10.3 10.9 0.14 15.7 16.5 15.8 0.32 0.41
(10.0, 10.7) (10.0, 10.6) (10.4, 11.4) (14.9, 16.5) (15.7, 17.2) (15.1, 16.5)
DHA, wt% 0.97 0.95 0.89 0.54 0.60 0.68 0.65 0.49 0.33
(0.86, 1.07) (0.87, 1.03) (0.81, 0.98) (0.55, 0.65) (0.61, 0.75) (0.57, 0.72)
AA, wt% 0.40 0.39 0.39 0.73 0.63 0.62 0.61 0.65 0.48
(0.38, 0.42) (0.37, 0.40) (0.37, 0.41) (0.60, 0.65) (0.59, 0.64) (0.59, 0.64)
n6:n3 7.2 7.0 7.4 0.57 12.4 12.4 11.8 0.50 0.80
(6.6, 7.8) (6.5, 7.5) (6.8, 7.9) (11.6, 13.2) (11.3, 13.5) (11.0, 12.6)
a P-values obtained by ANOVA.
b Median (25th percentile, 75th percentile), all such values.
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higher end and the Ghana values on the lower end of normal. It is
possible that SQ-LNS had an impact on breast milk ALA in Ghana but
no other fatty acids due to low dietary intake of ALA but high dietary
intake of DHA. It is unclear why there was not a similar eﬀect in
Malawi. Women in the Malawi trial had higher breast milk ALA than
those in Ghana, perhaps indicating less ability to respond to additional
ALA. The women in the Malawi trial also had poorer indicators of
health status (higher prevalence of anemia and malaria), which may
have resulted in reduced correlation between fatty acid intake and fatty
acid biomarkers in plasma. A recent study showed that in a Swedish
population in which seafood intake was correlated with serum DHA,
there was no such correlation among individuals with atopic eczema
[36], raising the possibility that other health conditions might be
associated with discordance between fatty acid intake and biomarkers.
The diﬀerent levels of micronutrients provided in the three diﬀerent
supplements may have also impacted women's fatty acid status (i.e.,
excess iron can lead to lipid oxidation of fatty acids [37]; antioxidants,
such as vitamin E [α-tocopherol], can prevent oxidation of fatty acids
[38]). MMN and SQ-LNS had the same micronutrient content, except
that SQ-LNS also contained magnesium, phosphorus, calcium, and
potassium. While it is unlikely the addition of phosphorus, calcium, or
potassium aﬀected fatty acid levels, some research in animal models
has demonstrated that deﬁciency in magnesium can result in lower
PUFA concentrations [39].
Peanut consumption has been associated with improved plasma
lipid proﬁles in several studies, including a trial in Ghana [17,40,41].
Given that SQ-LNS is peanut-based, we had hypothesized that SQ-LNS
may impact plasma lipid proﬁles of the women receiving this supple-
ment. There are several possible explanations for the lack of an eﬀect of
SQ-LNS on plasma lipids in this study. First, it is possible that the dose
of SQ-LNS was too small to produce an eﬀect. Second, the majority of
the plasma lipid concentrations at enrollment were within the normal
range for healthy adults, so it is possible that there was limited
opportunity for improvement. Lastly, cholesterol and triglyceride
concentrations increase over the course of pregnancy [14] and there-
fore the cholesterol and triglyceride lowering-eﬀect associated with
peanut consumption might be masked by the increase in both of these
plasma lipids during pregnancy.
Strengths of this study include rigorous follow-up and monitoring
of compliance, the large sample size within a randomized controlled
trial study design, and the long duration of supplementation. Women
were enrolled in the trials at a mean of 16–17 wk gestation and
received supplementation through pregnancy and up to 6 months
postpartum, which approximates 56 wk of supplementation.
Previously, the longest duration of ALA supplementation in a trial that
measured fatty acid status was 42 wk [7,42]. Duration of ALA
supplementation has been shown to be a factor with regard to eﬀects
on LCPUFAs, as a trial in Japanese men reported no eﬀect in DHA at 3
mo, but increased levels of DHA after 10 mo of supplementation [42].
There are limitations to this study. Our trials experienced loss to
follow-up, however we conducted sensitivity analyses and did not ﬁnd
evidence of this leading to a bias in results, except for a bias towards
the null for breast milk fatty acids from the Ghana trial. It was not
possible to blind women to whether they were assigned SQ-LNS vs. a
capsule, however we think it is unlikely that this partial blinding
inﬂuenced these results as lab technicians were blinded. Diﬀerent
laboratories were used to analyze the plasma lipids and diﬀerent
methods of breast milk collection were used between the two trials,
so we cannot exclude the possibility that diﬀerences in plasma lipids or
breast milk fatty acid levels between the two populations may be due to
method of laboratory analysis and collection, respectively. However,
expressing fatty acid levels as the percentage of total fatty acids by
weight should eliminate bias due to diﬀerences in total milk fat
concentrations. Fatty acids were analyzed in plasma as opposed to
erythrocytes, which may have led to greater within-person variability
[43]. Plasma fatty acids are more strongly inﬂuenced by recent intake
compared to erythrocytes [44]. Because of the diﬃculty of obtaining
fasting blood samples from pregnant women, non-fasting blood
samples were collected. However, we collected information regarding
time between last meal and sample collection and included this in
adjusted models when signiﬁcant (p < 0.1). Typically, there is minimal
eﬀect of fasting on total cholesterol, HDL-C, and LDL-C, although
triglycerides tend to be approximately 15% higher in non-fasting vs.
fasting samples [45,46]. Lastly, we examined multiple outcomes and
thus our results demonstrating an impact of SQ-LNS on plasma and
breast milk ALA levels may be due to chance. However, we note that
the supplement contained ALA and previous studies support the
biological plausibility of an eﬀect on ALA levels without an eﬀect on
other fatty acid levels.
4.2. Conclusion
The current formulation of SQ-LNS may increase plasma ALA in
late pregnancy in settings similar to the study sites in Malawi and
Ghana, and may impact breast milk ALA levels in populations similar
to the study population in Ghana. Research to evaluate diﬀerent
formulations of SQ-LNS, particularly with higher amounts of ALA
and lower amounts of LA, would be beneﬁcial for further examining the
potential of SQ-LNS to aﬀect maternal fatty acid status.
Conﬂicts of interest
KHJ is employed by OmegaQuant Analytics, LLC, a commercial
laboratory that performed the fatty acid analysis for this study. The
other authors declare no conﬂicts of interest related to this study.
Names for PubMed indexing
Oaks, Dewey, Young, Adu-Afarwuah, Ashorn, Jackson, Lartey,
Maleta, Okronipa, Sadalaki, Baldiviez, Shahab-Ferdows, Vosti, Ashorn
Trial registration
ClinicalTrials.gov, Identiﬁers NCT00970866 (Ghana trial) and
NCT01239693 (Malawi trial).
Acknowledgements
We thank Stephen Vosti for his support in study design and logistics
regarding the socioeconomic variables; Mary Arimond for iLiNS
Project management; the iLiNS Steering Committee (http://ilins.org),
for providing leadership for the iLiNS-DYAD trials in Ghana and
Malawi; and the women who participated in the study.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at doi:10.1016/j.plefa.2017.01.007.
References
[1] L. Lauritzen, S.E. Carlson, Maternal fatty acid status during pregnancy and
lactation and relation to newborn and infant status, Matern. Child Nutr. 7 (2011)
41–58.
[2] J.A. Greenberg, S.J. Bell, W.V. Ausdal, Omega-3 fatty acid supplementation during
pregnancy, Rev. Obstet. Gynecol. 1 (2008) 162–169.
[3] G.C. Burdge, S.A. Wootton, Conversion of alpha-linolenic acid to eicosapentaenoic,
docosapentaenoic and docosahexaenoic acids in young women, Br. J. Nutr. 88
(2002) 411–420.
[4] L.C. Del Gobbo, F. Imamura, S. Aslibekyan, M. Marklund, J.K. Virtanen,
M. Wennberg, M.Y. Yakoob, S.E. Chiuve, L. Dela Cruz, A.C. Frazier-Wood,
A.M. Fretts, E. Guallar, C. Matsumoto, K. Prem, T. Tanaka, J.H. Wu, X. Zhou,
C. Helmer, E. Ingelsson, J.M. Yuan, P. Barberger-Gateau, H. Campos, P.H. Chaves,
L. Djousse, G.G. Giles, J. Gomez-Aracena, A.M. Hodge, F.B. Hu, J.H. Jansson,
I. Johansson, K.T. Khaw, W.P. Koh, R.N. Lemaitre, L. Lind, R.N. Luben,
B.M. Oaks et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 117 (2017) 28–35
34
E.B. Rimm, U. Riserus, C. Samieri, P.W. Franks, D.S. Siscovick, M. Stampfer,
L.M. Steﬀen, B.T. Steﬀen, M.Y. Tsai, R.M. van Dam, S. Voutilainen, W.C. Willett,
M. Woodward, D. Mozaﬀarian, omega-3 polyunsaturated fatty acid biomarkers and
coronary heart disease: pooling project of 19 cohort studies, JAMA Intern. Med.
176 (2016) 1155–1166.
[5] A. Pan, M. Chen, R. Chowdhury, J.H. Wu, Q. Sun, H. Campos, D. Mozaﬀarian,
F.B. Hu, alpha-linolenic acid and risk of cardiovascular disease: a systematic review
and meta-analysis, Am. J. Clin. Nutr. 96 (2012) 1262–1273.
[6] R.H.M. de Groot, G. Hornstra, A.C. van Houwelingen, F. Roumen, Eﬀect of alpha-
linolenic acid supplementation during pregnancy on maternal and neonatal
polyunsaturated fatty acid status and pregnancy outcome, Am. J. Clin. Nutr. 79
(2004) 251–260.
[7] J.T. Brenna, N. Salem Jr., A.J. Sinclair, S.C. Cunnane, Alpha-Linolenic acid
supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in
humans, Prostaglandins, Leukot., Essent. Fat. Acids 80 (2009) 85–91.
[8] R.A. Gibson, B. Muhlhausler, M. Makrides, Conversion of linoleic acid and alpha-
linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs), with a focus on
pregnancy, lactation and the ﬁrst 2 years of life, Matern. Child Nutr. 7 (2011)
17–26.
[9] K.F. Michaelsen, K.G. Dewey, A.B. Perez-Exposito, M. Nurhasan, L. Lauritzen,
N. Roos, Food sources and intake of n-6 and n-3 fatty acids in low-income countries
with emphasis on infants, young children (6–24 months), and pregnant and
lactating women, Matern. Child Nutr. 7 (2011) 124–140.
[10] L.M. Mudd, C.B. Holzman, J.M. Catov, P.K. Senagore, R.W. Evans, Maternal lipids
at mid-pregnancy and the risk of preterm delivery, Acta Obstet. Et. Gynecol. Scand.
91 (2012) 726–735.
[11] R.J. Edison, K. Berg, A. Remaley, R. Kelley, C. Rotimi, R.E. Stevenson, M. Muenke,
Adverse birth outcome among mothers with low serum cholesterol, Pediatrics 120
(2007) 723–733.
[12] C.M. Rosenberger, J.H. Brumell, B.B. Finlay, Microbial pathogenesis: lipid rafts as
pathogen portals, Curr. Biol. 10 (2000) R823–R825.
[13] L.A. Woollett, Where does fetal and embryonic cholesterol originate and what does
it do?, Annu. Rev. Nutr. 28 (2008) 97–114.
[14] A. Basaran, Pregnancy-induced hyperlipoproteinemia: review of the literature,
Reprod. Sci. 16 (2009) 431–437.
[15] B.W. Alleman, A.R. Smith, H.M. Byers, B. Bedell, K.K. Ryckman, J.C. Murray,
K.S. Borowski, A proposed method to predict preterm birth using clinical data,
standard maternal serum screening, and cholesterol, Am. J. Obstet. Gynecol. 208
(2013) (472.e471–472.411).
[16] T.G.M. Vrijkotte, N. Krukziener, B.A. Hutten, K.C. Vollebregt, M. van Eijsden,
M.B. Twickler, Maternal lipid proﬁle during early pregnancy and pregnancy
complications and outcomes: the ABCD study, J. Clin. Endocrinol. Metab. 97
(2012) 3917–3925.
[17] P. Lokko, A. Lartey, M. Armar-Klemesu, R.D. Mattes, Regular peanut consumption
improves plasma lipid levels in healthy Ghanaians, Int. J. Food Sci. Nutr. 58 (2007)
190–200.
[18] S. Adu-Afarwuah, A. Lartey, H. Okronipa, P. Ashorn, M. Zeilani, J.M. Peerson,
M. Arimond, S. Vosti, K.G. Dewey, Lipid-based nutrient supplement increases the
birth size of infants of primiparous women in Ghana, Am. J. Clin. Nutr. 101 (2015)
835–846.
[19] S. Adu-Afarwuah, A. Lartey, H. Okronipa, P. Ashorn, J.M. Peerson, M. Arimond,
U. Ashorn, M. Zeilani, S. Vosti, K.G. Dewey, Small-quantity, lipid-based nutrient
supplements provided to women during pregnancy and 6 mo postpartum and to
their infants from 6 mo of age increase the mean attained length of 18-mo-old
children in semi-urban Ghana: a randomized controlled trial, Am. J. Clin. Nutr.
(2016).
[20] P. Ashorn, L. Alho, U. Ashorn, Y.B. Cheung, K.G. Dewey, U. Harjunmaa, A. Lartey,
M. Nkhoma, N. Phiri, J. Phuka, S.A. Vosti, M. Zeilani, K. Maleta, The impact of
lipid-based nutrient supplement provision to pregnant women on newborn size in
rural Malawi: a randomized controlled trial, Am. J. Clin. Nutr. 101 (2015)
387–397.
[21] P. Ashorn, L. Alho, U. Ashorn, Y.B. Cheung, K.G. Dewey, A. Gondwe,
U. Harjunmaa, A. Lartey, N. Phiri, T.E. Phiri, S.A. Vosti, M. Zeilani, K. Maleta,
Supplementation of maternal diets during pregnancy and for 6 months postpartum
and infant diets thereafter with small-quantity lipid-based nutrient supplements
does not promote child growth by 18 months of age in rural Malawi: a randomized
controlled trial, J. Nutr. 145 (2015) 1345–1353.
[22] M.K. Mridha, S.L. Matias, C.M. Chaparro, R.R. Paul, S. Hussain, S.A. Vosti,
K.L. Harding, J.R. Cummins, L.T. Day, S.L. Saha, J.M. Peerson, K.G. Dewey, Lipid-
based nutrient supplements for pregnant women reduce newborn stunting in a
cluster-randomized controlled eﬀectiveness trial in Bangladesh, Am. J. Clin. Nutr.
103 (2016) 236–249.
[23] S.Y. Hess, S. Abbeddou, E.Y. Jimenez, J.W. Some, S.A. Vosti, Z.P. Ouedraogo,
R.M. Guissou, J.B. Ouedraogo, K.H. Brown, Small-quantity lipid-based nutrient
supplements, regardless of their zinc content, increase growth and reduce the
prevalence of stunting and wasting in young burkinabe children: a cluster-
randomized trial, PLoS One 10 (2015) e0122242.
[24] C. Mangani, K. Maleta, J. Phuka, Y.B. Cheung, C. Thakwalakwa, K. Dewey,
M. Manary, T. Puumalainen, P. Ashorn, Eﬀect of complementary feeding with lipid-
based nutrient supplements and corn-soy blend on the incidence of stunting and
linear growth among 6–18-month-old infants and children in rural Malawi,
Matern. Child Nutr. 11 (Suppl 4) (2015) 132–143.
[25] W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of concentration of low-
density lipoprotein cholesterol in plasma, without us of preparative ultracentrifuge,
Clin. Chem. 18 (1972) 499–502.
[26] G.R. Warnick, R.H. Knopp, V. Fitzpatrick, L. Branson, Estimating low-density
lipoprotein cholesterol by the Friedewald equation is adequate for classifying
patients on the basis of nationally recommended cutpoints, Clin. Chem. 36 (1990)
15–19.
[27] K. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C.
Fruchart, W.P.T. James, C.M. Loria, S.C. Smith, Harmonizing the Metabolic
Syndrome A Joint Interim Statement of the International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;
American Heart Association; World Heart Federation; International
Atherosclerosis Society; and International Association for the Study of Obesity,
Circulation, 120, 2009, 1640–1645.
[28] J.I. Cleeman, S.M. Grundy, D. Becker, L.T. Clark, R.S. Cooper, M.A. Denke,
W.J. Howard, D.B. Hunninghake, D.R. Illingworth, R.V. Luepker, P. McBride,
J.M. McKenney, R.C. Pasternak, N.J. Stone, L. Van Horn, H.B. Brewer, N.D. Ernst,
D. Gordon, D. Levy, B. Rifkind, J.E. Rossouw, P. Savage, S.M. Haﬀner, D.G. Orloﬀ,
M.A. Proschan, J.S. Schwartz, C.T. Sempos, S.T. Shero, E.Z. Murray, E. Natl,
cholesterol Educ program, executive summary of the third report of the national
cholesterol education program (NCEP) expert panel on detection, evaluation, and
treatment of high blood cholesterol in adults (adult treatment panel III), Jama-J.
Am. Med. Assoc. 285 (2001) 2486–2497.
[29] J. Coates, A. Swindale, P. Bilinsky, Household Food Insecurity Access Scale
(HFIAS) for Measurement of Household Food Access: Indicator Guide (v. 3), FHI/
FANTA, 2007.
[30] S. Vyas, L. Kumaranayake, Constructing socio-economic status indices: how to use
principal components analysis, Health Policy Plan 21 (2006) 459–468.
[31] D.L. Streiner, Best (but oft-forgotten) practices: the multiple problems of multi-
plicity-whether and how to correct for many statistical tests, Am. J. Clin. Nutr.
(2015).
[32] K.E. Wood, E. Mantzioris, R.A. Gibson, C.E. Ramsden, B.S. Muhlhausler, The eﬀect
of modifying dietary LA and ALA intakes on omega-3 long chain polyunsaturated
fatty acid (n-3 LCPUFA) status in human adults: a systematic review and
commentary, Prostaglandins Leukot. Essent. Fat. Acids 95 (2015) 47–55.
[33] E.Y. Jimenez, C. Mangani, P. Ashorn, W.S. Harris, K. Maleta, K.G. Dewey, Breast
milk from women living near Lake Malawi is high in docosahexaenoic acid and
arachidonic acid, Prostaglandins Leukot. Essent. Fat. Acids 95 (2015) 71–78.
[34] J.T. Brenna, B. Varamini, R.G. Jensen, D.A. Diersen-Schade, J.A. Boettcher,
L.M. Arterburn, Docosahexaenoic and arachidonic acid concentrations in human
breast milk worldwide, Am. J. Clin. Nutr. 85 (2007) 1457–1464.
[35] K.H. Jackson, J. Polreis, L. Sanborn, D. Chaima, W.S. Harris, Analysis of breast
milk fatty acid composition using dried milk samples, Int. Breastfeed. J. 11 (2016)
1.
[36] M. Barman, K. Jonsson, A. Sandin, A.E. Wold, A.S. Sandberg, Serum fatty acid
proﬁle does not reﬂect seafood intake in adolescents with atopic eczema, Acta
Paediatr. 103 (2014) 968–976.
[37] F.Q. Schafer, S.Y. Qian, G.R. Buettner, Iron and free radical oxidations in cell
membranes, Cell. Mol. Biol. 46 (2000) 657–662.
[38] S. Peter, U. Moser, S. Pilz, M. Eggersdorfer, P. Weber, The challenge of setting
appropriate intake recommendations for vitamin E: considerations on status and
functionality to deﬁne nutrient requirements, Int. journal for Vitamin Nutr. Res.
Int. Zeitschrift fur Vitamin- und Ernahrungsforschung. J. Int. de Vitaminol. et de
Nutr. 83 (2013) 129–136.
[39] M. Gupta, M.H. Solanki, P.K. Chatterjee, X. Xue, A. Roman, N. Desai, B. Rochelson,
C.N. Metz, Maternal magnesium deﬁciency in mice leads to maternal metabolic
dysfunction and altered lipid metabolism with fetal growth restriction, Mol. Med.
20 (2014) 332–340.
[40] D.J. O'Byrne, D.A. Knauft, R.B. Shireman, Low fat-monounsaturated rich diets
containing high-oleic peanuts improve serum lipoprotein proﬁles, Lipids 32 (1997)
687–695.
[41] C.M. Alper, R.D. Mattes, Peanut consumption improves indices of cardiovascular
disease risk in healthy adults, J. Am. Coll. Nutr. 22 (2003) 133–141.
[42] O. Ezaki, M. Takahashi, T. Shigematsu, K. Shimamura, J. Kimura, H. Ezaki,
T. Gotoh, Long-term eﬀects of dietary alpha-linolenic acid from perilla oil on serum
fatty acids composition and on the risk factors of coronary heart disease in
Japanese elderly subjects, J. Nutr. Sci. Vitaminol. 45 (1999) 759–772.
[43] W.S. Harris, R.M. Thomas, Biological variability of blood omega-3 biomarkers,
Clin. Biochem. 43 (2010) 338–340.
[44] W.S. Harris, S.A. Varvel, J.V. Pottala, G.R. Warnick, J.P. McConnell, Comparative
eﬀects of an acute dose of ﬁsh oil on omega-3 fatty acid levels in red blood cells
versus plasma: implications for clinical utility, J. Clin. Lipido. 7 (2013) 433–440.
[45] S. Mora, N. Rifai, J.E. Buring, P.M. Ridker, Fasting compared with nonfasting
lipids and apolipoproteins for predicting incident cardiovascular events, Circulation
118 (2008) 993–1001.
[46] A. Langsted, J.J. Freiberg, B.G. Nordestgaard, Fasting and nonfasting lipid levels
inﬂuence of normal food intake on lipids, lipoproteins, apolipoproteins, and
cardiovascular risk prediction, Circulation 118 (2008) 2047–2056.
B.M. Oaks et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 117 (2017) 28–35
35
